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Cisplatin 
nephrotoxicity
Among the many models of acute renal 
failure (acute kidney injury is the new 
name), cisplatin nephrotoxicity has an 
‘exact’ counterpart, since many patients 
undergoing chemotherapy with this 
agent develop the disease. Cisplatin 
induces the production of tumor 
necrosis factor-α (TNF-α), which is 
thought to be the proximate cause of 
nephrotoxicity. Because in vitro studies 
show that the drug produces TNF-α 
in many cell types, the question arises 
of whether the disease is produced by 
tubular epithelial cells or by invading 
or resident bone marrow-derived 
cells that respond to the agent by 
producing the harmful cytokine. As 
they report in this issue, Zhang et al. 
ablated the bone marrow of mice and 
infused them with bone marrow cells 
taken from wild-type mice or mice 
that had their TNF-α gene deleted. 
In companion studies, they infused 
genetically normal bone marrow cells 
or TNF-α-deleted bone marrow cells 
into mice with their TNF-α deleted. 
Regardless of the source of immune 
cells, mice with no TNF-α in their 
kidney parenchyma had less severe 
renal failure than those with intact 
TNF-α. Hence, TNF-α was produced 
by the kidney itself, presumably by the 
epithelium. See page 37.
Cisplatin causes apoptosis of tubular 
epithelial cells, which is mediated 
by the release of cytochrome c from 
mitochondria and followed by 
activation of caspases. In a related 
paper, Wei et al. studied the role of Bax, 
a proapoptotic protein that induces 
the release of cytochrome c. Cisplatin 
led to the accumulation of Bax in 
mitochondria. However, the release of 
cytochrome c was attenuated in mice 
whose Bax gene was deleted. Further, 
the Bax knockout mice had partially 
but signifi cantly preserved kidney 
function aft er they were given cisplatin. 
See page 53.
Bariatric surgery and 
kidney stones
With the epidemic of obesity hitting the 
United States hard, numerous surgical 
procedures have been developed to 
help the severely obese reduce caloric 
intake and lose weight. Roux-en-Y 
bypass surgery is the most common of 
these successful procedures. In a new 
study, Sinha et al. followed 60 patients 
who had developed kidney stones 
aft er Roux-en-Y bypass surgery. Th ese 
patients lost massive amounts of weight 
aft er receiving the surgery but had an 
average of more than two stone episodes 
per year. In most of these patients, 
metabolic studies showed that some had 
calcium oxalate stones whereas others 
had mixed oxalate and urate stones. 
Even patients who did not have kidney 
stones had hyperoxaluria aft er the 
procedure. In a small random sampling 
of patients undergoing this bypass 
procedure, hyperoxaluria was rare 
preoperatively but common 12 months 
aft er surgery. Th ough these studies 
were not prospective or controlled, 
the results are striking. Even more 
puzzling is the potential mechanism 
by which reduction of body mass leads 
to hyperoxaluria. It is necessary to see 
whether other surgical weight-loss 
procedures lead to the same outcome; 
could kidney stones be a consequence 
of the Roux-en-Y operation, or are 
they due to the massive reduction 
of fat tissues? Th is is an interesting 
observation that will lead to a new area 
of investigation. See page 100.
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RYGB, Roux-en-Y gastric bypass; CaOx SS, 
calcium oxalate supersaturation; DG, delta 
Gibbs units.  
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